Long‐term clinical results of posterior chamber phakic intraocular lens implantation to correct myopia

Lee, Jong-Soo; Kim, Young‐Hee; Park, Young Min; Bae, Jungae; Lee, Seunguk; Park, Young-Min; Lee, Jong-Hun; Lee, Jieun

doi:10.1111/ceo.12691

Cited by 79 publications

(53 citation statements)

References 38 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, similar to other phakic IOL implantation series in the literature, the expected increase in UDVA after the Eyecryl phakic IOL implantation was observed (5,8). The safety index in this study was >1.0, indicating that the mean patient CDVA had increased after the operation.…”

Section: Discussionsupporting

confidence: 87%

“…They reported that the regression between the first and third years was statistically significant. Lee et al (5) reported that the mean SE had decreased to -0.58±0.72 D in patients with a follow-up period of at least 5 years and 69.8% of the patients were within ±0.50 D. Guber et al (16) reported a safety index of 1.25±0.57 at the 10-year followup with an average SE of 0.7 D. Moya et al (15) stated that the SE was -1.77±1.93 D in the last examination of 144 patients after 12 years of follow-up. The relatively good refractive outcomes in the early period and the high efficacy index in the long run, despite myopic shifts, are common points in all of these studies and in our study.…”

Section: Discussionmentioning

confidence: 99%

“…Despite satisfactory refractive results, many angle-supported phakic IOLs have been removed from the market due to late complications (1)(2)(3). On the other hand, several studies have reported positive results with regard to the efficacy and safety of iris-claw and posterior chamber phakic IOLs (4)(5)(6)(7)(8)(9). The US Food and Drug Administration determined that the efficacy and safety of iris-claw phakic and posterior chamber phakic IOLs were within the acceptable limits (4,10).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Refractive Results and Endothelial Cell Density After Eyecryl Phakic Intraocular Lens Implantation

Ürdem¹

2019

Beyoglu Eye J

View full text Add to dashboard Cite

This study was an examination of the refractive results and complications encountered with implantation of the Eyecryl phakic intraocular lens (IOL) (Biotech Vision Care, Luzern, Switzerland). Methods: IOL recipients with a follow-up period of at least 2 years were included the study. Uncorrected and corrected distance visual acuity (UDVA and CDVA, respectively), central endothelial cell density (ECD), and procedure-related complication data were recorded. Results: The study included 52 eyes from 26 patients. The efficacy index (postoperative UDVA/preoperative CDVA) was 1.32±1.09 in the first year and 1.39±1.03 in the second year. The safety index (postoperative CDVA/preoperative CDVA) was 1.69±1.16 at the last follow-up. None of the patients lost 2 or more lines of CDVA. The mean ECD loss was-4.51±9.69% at 1 year (p=0.005). There was no statistically significant ECD loss between the 1-and 2-year follow-up visits (p=0.794). Conclusion: The results of Eyecryl phakic IOL implantation were favorable in terms of efficacy and safety.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Refractive Results and Endothelial Cell Density After Eyecryl Phakic Intraocular Lens Implantation

Ürdem¹

2019

Beyoglu Eye J

View full text Add to dashboard Cite

show abstract

“…Second, the optical quality of the eye decreases with aging [27] . In our research, the average age of the subjects was 39.16 ± 7.52, older than previously reported subjects [28,29] . We postulated that the crystal density increases with age, and the intraocular scattering index also increases.…”

Section: Discussioncontrasting

confidence: 57%

Implantable collamer lens with a central hole for residual refractive error correction after corneal refractive surgery

Zhang

Zhu

et al. 2019

Preprint

View full text Add to dashboard Cite

PURPOSE: To assess the visual and refractive outcomes of an implantable collamer lens with a central hole (ICL V4c) for residual refractive error correction after corneal refractive surgery in individuals with myopia. DESIGN: Prospective, nonrandomized observational case series (self-controlled). METHODS: We investigated 16 eyes of eight consecutive patients with myopia undergoing ICL V4c implantation after corneal refractive surgery. The uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA) were examined before surgery and 1 month, 3 months, and 6 months after surgery. We quantitatively assessed the postoperative values of the modulation transfer function (MTF) cutoff frequency, Strehl ratio, objective scattering index (OSI), and OQAS values (OVs) by using an Optical Quality Analysis System. RESULTS: At 6 months after surgery, the mean uncorrected logMAR VA was 0.06 ± 0.10, and the values had improved in 100% of the eyes. The mean MTF cutoff frequency, Strehl ratio, OSI, OV 100%, OV 20%, and OV 9%, were 31.29 ± 4.32 cycles/degree (c/d), 0.18 ± 0.04, 1.469 ± 0.47, 0.97 ± 0.26, 0.75 ± 0.29, and 0.51 ± 0.23 at 6 months after ICL V4c implantation, respectively. CONCLUSION: ICL V4c implantation was safe and effective for the correction of residual refractive error after corneal refractive surgeries, and it had excellent optical performance.

show abstract

“…In a report of 3-year follow-up of 526 eyes of 294 patients with mean preoperative MRSE of −10.06±3.74 D participating in the US FDA clinical trial of the ICL, 59.3% had 20/20 or better uncorrected visual acuity (UCVA), and 94.7% had 20/40 or better UCVA if best-corrected visual acuity was 20/20 and they were targeted for emmetropia; 67.5% of patients were within 0.5 D and 88.2% were within 1.0 D of predicted refraction. 4 Lee et al 12 reported 281 eyes of 145 patients who were followed for at least 5 years (mean =87±18.9 months) and had mean preoperative MRSE of −8.74±2.27 D (−4.00 to −15.25 D). They noted 60.5% UCVA 20/20 or better: At the end of follow up, the postoperative logMAR uncorrected distance visual acuity (UDVA) was 0.30 (approximately 6/12) or better in 254 eyes (90.4%), 0.10 (approximately 6/7.5) or better in 238 eyes (84.7%) and 0.00 (6/6) or better in 170 eyes (60.5%).…”

Section: Effectiveness: Refractive Outcomesmentioning

confidence: 99%

Meta-analysis and review: effectiveness, safety, and central port design of the intraocular collamer lens

Packer¹

2016

OPTH

219

198

View full text Add to dashboard Cite

The purpose of this review is to summarize relevant data from publications appearing in the peer-reviewed scientific literature over the past decade since US Food and Drug Administration approval of the implantable collamer lens (ICL), and, in particular, to review studies relating to sizing methodology, safety, and effectiveness, as well as more recent studies reporting clinical outcomes of the V4c Visian ICL with KS Aquaport, VICMO. A literature search was conducted using two databases, PubMed.gov and Science.gov, to identify all articles published after 2005 related to the Visian ICL (STAAR Surgical, Inc.). Articles were examined for their relevance to sizing methodology, clinical safety, and effectiveness, and the references cited in each article were also searched for additional relevant publications. The literature review revealed that all currently reported methods of determining the best-fit size of the ICL achieve similarly satisfactory results in terms of vault, the safe distance between the crystalline lens and the ICL. Specifically, meta-analysis demonstrated that sulcus-to-sulcus and white-to-white measurement-based sizing methods do not result in clinically meaningful nor statistically significant differences in vault (two-sample two-sided t-test using pooled mean and standard deviations; t (2,594)=1.33; P=0.18). The reported rates of complications related to vault are very low, except in two case series where additional risk factors such as higher levels of myopia and older age impacted the incidence of cataract. On the basis of preclinical studies and initial clinical reports, with up to 5 years of follow-up, the new VICMO central port design holds promise for further reduction of complications. Given its safety record and the significant improvement in vision and quality of life that the ICL makes possible, the benefits of ICL implantation outweigh the risks.

show abstract

Long‐term clinical results of posterior chamber phakic intraocular lens implantation to correct myopia

Abstract: Background: The aim of this study was to determine whether implantable collamer lens (ICL) implantation to correct myopia is an effective and safe surgical option even after long-term follow up.

Cited by 79 publications

References 38 publications

Refractive Results and Endothelial Cell Density After Eyecryl Phakic Intraocular Lens Implantation

Refractive Results and Endothelial Cell Density After Eyecryl Phakic Intraocular Lens Implantation

Implantable collamer lens with a central hole for residual refractive error correction after corneal refractive surgery

Meta-analysis and review: effectiveness, safety, and central port design of the intraocular collamer lens

Contact Info

Product

Resources

About